CYP2C19 activity comparison between Swedes and Koreans: Effect of genotype, sex, oral contraceptive use, and smoking

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 871-877

  Ramsjö, Margareta ^a   Aklillu, Eleni ^a   Bohman, Lilleba ^a   Ingelman Sundberg, Magnus ^b   Roh, Hyung Keun ^c   Bertilsson, Leif ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Gachon University College of Medicine   (South Korea)

Author keywords

CYP2C19; Gender; Korean; Omeprazole; Swedes

Indexed keywords

5 HYDROXYOMEPRAZOLE; CAFFEINE; CYTOCHROME P450 2C19; DEBRISOQUINE; DRUG METABOLITE; LOSARTAN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; QUININE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EPIGENETICS; FEMALE; GENE FREQUENCY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEREDITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; ORAL CONTRACEPTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING HABIT; SWEDEN;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CONTRACEPTIVES, ORAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; KOREA; MALE; SEX FACTORS; SMOKING; SWEDEN;

EID: 77956181414     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0835-0     Document Type: Article

References (29)

1. K Brosen 2004 Some aspects of genetic polymorphism in the biotransformation of antidepressants Therapie 59 1 5 12 10.2515/therapie:2004003 15199661
2. L Bertilsson TK Henthorn E Sanz G Tybring J Sawe T Villen 1989 Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype Clin Pharmacol Ther 45 4 348 355 1:CAS:528:DyaL1MXit1Cqt74%3D 2495208
3. SA Ward NA Helsby E Skjelbo K Brosen LF Gram AM Breckenridge 1991 The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-a panel study Br J Clin Pharmacol 31 6 689 692 1:CAS:528:DyaK3MXks1equr4%3D 1867963
4. XQ Li TB Andersson M Ahlstrom L Weidolf 2004 Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities Drug Metab Dispos 32 8 821 827 10.1124/dmd.32.8.821 1:CAS:528: DC%2BD2cXmtFCjt7Y%3D 15258107
5. T Andersson JO Miners ME Veronese W Tassaneeyakul UA Meyer DJ Birkett 1993 Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism Br J Clin Pharmacol 36 6 521 530 1:CAS:528:DyaK2cXhsFaruro%3D 12959268
6. K Laine G Tybring L Bertilsson 2000 No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects Clin Pharmacol Ther 68 2 151 159 10.1067/mcp.2000.108949 1:CAS:528: DC%2BD3cXmsFamu7Y%3D 10976546
7. M Chang ML Dahl G Tybring E Gotharson L Bertilsson 1995 Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Pharmacogenetics 5 6 358 363 10.1097/00008571-199512000-00004 1:CAS:528:DyaK28XhtFyitrc%3D 8747407
8. G Alvan P Bechtel L Iselius U Gundert-Remy 1990 Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations Eur J Clin Pharmacol 39 6 533 537 10.1007/BF00316090 1:CAS:528:DyaK3MXhsFKmtr4%3D 2151318
9. M Jurima T Inaba D Kadar W Kalow 1985 Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians Br J Clin Pharmacol 19 4 483 487 1:CAS:528:DyaL2MXkvVWhsr0%3D 3994895
10. K Nakamura F Goto WA Ray CB McAllister E Jacqz GR Wilkinson RA Branch 1985 Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations Clin Pharmacol Ther 38 4 402 408 1:STN:280:DyaL28%2FgtlWksQ%3D%3D 4042523
11. Y Horai M Nakano T Ishizaki K Ishikawa HH Zhou BI Zhou CL Liao LM Zhang 1989 Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese Clin Pharmacol Ther 46 2 198 207 1:CAS:528:DyaL1MXls1Kks7w%3D 2758729
12. L Bertilsson YQ Lou YL Du Y Liu TY Kuang XM Liao KY Wang J Reviriego L Iselius F Sjoqvist 1992 Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin Clin Pharmacol Ther 51 4 388 397 1:CAS:528:DyaK38Xit1Olsbs%3D 1345344
13. T Ishizaki DR Sohn K Kobayashi K Chiba KH Lee SG Shin T Andersson CG Regardh YC Lou Y Zhang, et al. 1994 Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals Ther Drug Monit 16 2 214 215 10.1097/00007691- 199404000-00018 1:STN:280:DyaK2c3nvVylsg%3D%3D 8009572
14. HK Roh ML Dahl G Tybring H Yamada YN Cha L Bertilsson 1996 CYP2C19 genotype and phenotype determined by omeprazole in a Korean population Pharmacogenetics 6 6 547 551 10.1097/00008571-199612000-00008 1:CAS:528:DyaK2sXnvFOjtQ%3D%3D 9014204
15. SM de Morais GR Wilkinson J Blaisdell K Nakamura UA Meyer JA Goldstein 1994 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 22 15419 15422 8195181
16. SM De Morais GR Wilkinson J Blaisdell UA Meyer K Nakamura JA Goldstein 1994 Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 4 594 598 7969038
17. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson M Ingelman-Sundberg 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 1 103 113 10.1016/j.clpt.2005.10.002 1:CAS:528:DC%2BD28XksVGltw%3D%3D 16413245
18. M Sandberg I Johansson M Christensen A Rane E Eliasson 2004 The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype Drug Metab Dispos 32 5 484 489 10.1124/dmd.32.5.484 1:CAS:528:DC%2BD2cXjs1GrsL0%3D 15100169
19. N Djordjevic R Ghotbi L Bertilsson S Jankovic E Aklillu 2008 Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes Eur J Clin Pharmacol 64 4 381 385 10.1007/s00228-007-0438-6 1:CAS:528:DC%2BD1cXisFCmsbo%3D 18157525
20. R Ghotbi M Christensen HK Roh M Ingelman-Sundberg E Aklillu L Bertilsson 2007 Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans Eur J Clin Pharmacol 63 6 537 546 10.1007/s00228-007-0288-2 1:CAS:528:DC%2BD2sXkslWns70%3D 17370067
21. M Christensen K Andersson P Dalen RA Mirghani GJ Muirhead A Nordmark G Tybring A Wahlberg U Yasar L Bertilsson 2003 The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes Clin Pharmacol Ther 73 6 517 528 10.1016/S0009-9236(03)00050-X 1:CAS:528:DC%2BD3sXkt1Ortbw%3D 12811361
22. G Tybring Y Bottiger J Widen L Bertilsson 1997 Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects Clin Pharmacol Ther 62 2 129 137 10.1016/S0009-9236(97)90060-6 1:CAS:528: DyaK2sXmtVGju7g%3D 9284848
23. HG Xie SL Huang ZH Xu ZS Xiao N He HH Zhou 1997 Evidence for the effect of gender on activity of (S)-mephenytoin 4′-hydroxylase (CYP2C19) in a Chinese population Pharmacogenetics 7 2 115 119 10.1097/00008571-199704000-00004 1:CAS:528:DyaK2sXjvF2ntLY%3D 9170148
24. A Gomez M Ingelman-Sundberg 2009 Pharmacoepigenetics: its role in interindividual differences in drug response Clin Pharmacol Ther 85 4 426 430 10.1038/clpt.2009.2 1:CAS:528:DC%2BD1MXjtlSmtbY%3D 19242404
25. JI Kim YS Ju H Park S Kim S Lee JH Yi J Mudge NA Miller D Hong CJ Bell HS Kim IS Chung WC Lee JS Lee SH Seo JY Yun HN Woo H Lee D Suh HJ Kim M Yavartanoo M Kwak Y Zheng MK Lee JY Kim O Gokcumen RE Mills AW Zaranek J Thakuria X Wu RW Kim JJ Huntley S Luo GP Schroth TD Wu H Kim KS Yang WY Park GM Church C Lee SF Kingsmore JS Seo 2009 A highly annotated whole-genome sequence of a Korean individual Nature 460 7258 1011 1015 1:CAS:528:DC%2BD1MXotlSgurs%3D 19587683
26. WJ Tamminga J Wemer B Oosterhuis J Weiling B Wilffert LF de Leij RA de Zeeuw JH Jonkman 1999 CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences Eur J Clin Pharmacol 55 3 177 184 10.1007/s002280050615 1:CAS:528:DyaK1MXivVKgs7c%3D 10379632
27. S Hagg O Spigset R Dahlqvist 2001 Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers Br J Clin Pharmacol 51 2 169 173 10.1111/j.1365-2125.2001.01328.x 1:CAS:528: DC%2BD3MXislCrsL8%3D 11259990
28. S Palovaara G Tybring K Laine 2003 The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects Br J Clin Pharmacol 56 2 232 237 10.1046/j.1365-2125.2003.01868. x 1:CAS:528:DC%2BD3sXnsVeku7k%3D 12895199
29. T Suzuki K Matsuo A Sawaki K Wakai K Hirose H Ito T Saito T Nakamura K Yamao N Hamajima K Tajima 2007 Influence of smoking and CYP2C19 genotypes on H. pylori eradication success Epidemiol Infect 135 1 171 176 10.1017/ S0950268806006613 1:CAS:528:DC%2BD28Xht1Cmu7rN 16740190